BioNTech buys out partner Biotheus for PD-L1/VEGF cancer drugnews2024-11-13T11:45:55+00:00November 13th, 2024|Endpoints News|
AstraZeneca CEO reaffirms commitment to China following executive’s detentionnews2024-11-12T20:43:03+00:00November 12th, 2024|Endpoints News|
Merck KGaA plans China submission after late-stage win for tumor drugnews2024-11-12T16:09:12+00:00November 12th, 2024|Endpoints News|
Pfizer to invest $1B in China over next five years — reportsnews2024-11-07T20:13:39+00:00November 7th, 2024|Endpoints News|
Senior AstraZeneca exec detained in China amid wider investigationnews2024-11-07T19:54:33+00:00November 7th, 2024|Endpoints News|
Joe Jimenez’s latest Aditum company lines up T cell engager from Chinanews2024-11-07T12:03:51+00:00November 7th, 2024|Endpoints News|
Q&A: GSK’s CEO Emma Walmsley on the new Trump administration, trust, AI and Chinanews2024-11-06T18:49:02+00:00November 6th, 2024|Endpoints News|
Baxter pulls IV products out of China to shift supply to the USnews2024-11-01T11:59:38+00:00November 1st, 2024|Endpoints News|
Gardasil demand in China sinks, and Merck expects the same next quarternews2024-10-31T17:33:18+00:00October 31st, 2024|Endpoints News|
AstraZeneca China exec probed by local authoritiesnews2024-10-30T15:15:13+00:00October 30th, 2024|Endpoints News|
